N,2-dimethyl-1H-indol-5-amine | 71422-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: N,2-dimethyl-1H-indol-5-amine
• 英文别名: methyl-(2-methyl-indol-5-yl)-amine
• CAS: 71422-32-7
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: WOWCGXVJVYSKMN-UHFFFAOYSA-N

物化性质

• 熔点：
  105-106 °C(Solvent: Heptane)
• 沸点：
  347.9±22.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-氨基烟酸 、 N,2-dimethyl-1H-indol-5-amine 在 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.67h， 以86%的产率得到2-amino-N-methyl-N-(2-methyl-1H-indol-5-yl)nicotinamide
  参考文献：
  名称：

  Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway

  摘要：

  A high-throughput screen to discover inhibitors of p97 ATPase activity identified an indole amide that bound to an allosteric site of the protein. Medicinal chemistry optimization led to improvements in potency and solubility. Indole amide 3 represents a novel uncompetitive inhibitor with excellent physical and pharmaceutical properties that can be used as a starting point for drug discovery efforts.

  DOI：

  10.1021/acsmedchemlett.5b00396
• 作为产物：
  描述：

  5-氨基-2-甲基吲哚 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 4.17h， 生成 N,2-dimethyl-1H-indol-5-amine
  参考文献：
  名称：

  Allosteric Indole Amide Inhibitors of p97: Identification of a Novel Probe of the Ubiquitin Pathway

  摘要：

  A high-throughput screen to discover inhibitors of p97 ATPase activity identified an indole amide that bound to an allosteric site of the protein. Medicinal chemistry optimization led to improvements in potency and solubility. Indole amide 3 represents a novel uncompetitive inhibitor with excellent physical and pharmaceutical properties that can be used as a starting point for drug discovery efforts.

  DOI：

  10.1021/acsmedchemlett.5b00396

文献信息

• [EN] ERR INVERSE AGONISTS<br/>[FR] AGONISTES INVERSES D'ERR
  申请人：UNIV SAINT LOUIS

  公开号：WO2019036562A1

  公开（公告）日：2019-02-21

  In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.

  在一方面，本公开描述了新的雌激素受体相关孤儿受体（EER）反向激动剂化合物。还描述了药物制剂、合成方法及其用途。
• [EN] TRIOXACARCIN ANALOGS AND DIMERS AS POTENT ANTICANCER AGENTS<br/>[FR] ANALOGUES ET DIMÈRES DE TRIOXACARCINE EN TANT QU'AGENTS ANTICANCÉREUX PUISSANTS
  申请人：UNIV RICE WILLIAM M

  公开号：WO2019036537A1

  公开（公告）日：2019-02-21

  In one aspect, the present disclosure provides trioxacarcin analogs of the formula: wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein as well as dimers of the compounds described herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

  在一个方面，本公开提供了以下式的三氧环霉素类似物：其中变量如本文所定义。在另一个方面，本公开还提供了制备本文所披露的化合物以及本文所描述的二聚体的方法。在另一个方面，本公开还提供了药物组合物和使用本文所披露的化合物的方法。此外，还提供了具有化合物的细胞靶向基团的药物结合物。
• [EN] CONJUGATED ANTICANCER SMAC ANALOGS<br/>[FR] ANALOGUES SMAC ANTICANCÉREUX CONJUGUÉS
  申请人：UNIV CALIFORNIA

  公开号：WO2017044592A1

  公开（公告）日：2017-03-16

  Lipid-conjugated monovalent and bivalent secondary mitochondria derived activator of caspases (Smac) derivatives were synthesized and examined for in vitro and in vivo anticancer activity. Methods for treating cancer with these compounds are also disclosed.

  脂质共轭的一价和二价次级线粒体衍生的半胱氨酸蛋白酶激活剂（Smac）衍生物已被合成并用于体外和体内抗癌活性的检验。使用这些化合物治疗癌症的方法也被披露。
• [EN] DNA BINDING AGENTS WITH A MINOR GROOVE BINDING TAIL<br/>[FR] AGENTS LIANT L'ADN AVEC UNE QUEUE SE LIANT AU SILLON MINEUR
  申请人：UNIV TEXAS

  公开号：WO2017049091A1

  公开（公告）日：2017-03-23

  Provided herein are compounds which intercalate into the DNA of a cell and are capable of crossing the blood brain barrier of a formula provided herein. Pharmaceutical compositions of the compounds and methods of treating cancer, for example brain, lung, or pancreatic cancer, are also provided herein.

  本文提供的是一些能够插入细胞DNA并能够穿过血脑屏障的化合物。此外，本文还提供了这些化合物的药物组合物以及治疗癌症的方法，例如大脑、肺部或胰腺癌。
• [EN] EPOTHILONE ANALOGS, METHODS OF SYNTHESIS, METHODS OF TREATMENT, AND DRUG CONJUGATES THEREOF<br/>[FR] ANALOGUES D'ÉPOTHILONE, PROCÉDÉS DE SYNTHÈSE, PROCÉDÉS DE TRAITEMENT, ET CONJUGUÉS MÉDICAMENTEUX DE CEUX-CI
  申请人：UNIV RICE WILLIAM M

  公开号：WO2017066606A1

  公开（公告）日：2017-04-20

  In one aspect, the present disclosure provides epothilone analogs of the formula (I) wherein the variables are as defined herein. In another aspect, the present disclosure also provides methods of preparing the compounds disclosed herein. In another aspect, the present disclosure also provides pharmaceutical compositions and methods of use of the compounds disclosed herein. Additionally, drug conjugates with cell targeting moieties of the compounds are also provided.

  在一个方面，本公开提供了公式（I）中变量如本文所定义的紫杉醇类似物。在另一个方面，本公开还提供了制备本文披露的化合物的方法。在另一个方面，本公开还提供了药物组合物和使用本文披露的化合物的方法。此外，还提供了具有细胞靶向基团的药物共轭物。